The viral load monitoring cascade in HIV treatment programmes in sub-Saharan Africa: a systematic review

• Published in: BMC public health Vol. 24; no. 1; pp. 2603 - 17
• Main Authors: Kippen, Annalise, Nzimande, Londiwe, Gareta, Dickman, Iwuji, Collins
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 27.09.2024; BioMed Central; BMC
• Subjects: Acquired immune deficiency syndrome; Africa South of the Sahara - epidemiology; AIDS; Anti-HIV Agents - therapeutic use; Antiretroviral agents; Antiretroviral therapy; Care and treatment; Decentralisation; Diagnosis; Drug resistance; Failure cascade; Global health; Health risks; HIV; HIV infection; HIV Infections - drug therapy; Human immunodeficiency virus; Humans; Literature reviews; Measurement; Monitoring; Morbidity; Mortality; Nations; Patient outcomes; Public health; Sub-Saharan Africa; Systematic review; Viral Load; Viral load monitoring; Viremia; Africa South of the Sahara; Sub-Saharan Africa; Africa; Decentralisation; Viral load monitoring; HIV; Sub-Saharan Africa; Failure cascade
• ISSN: 1471-2458; 1471-2458
• DOI: 10.1186/s12889-024-20013-x

The United Nations' 95-95-95 (95% of people with HIV being aware of their diagnosis, 95% of those aware of their diagnosis being on treatment and 95% achieving viral suppression) target aims to reduce morbidity and mortality of HIV. However, with 60% of new HIV infections occurring in sub-Saharan Africa (SSA), achieving this target in the region is challenging. Viral load (VL) monitoring is the gold-standard approach of assessing treatment efficacy, and its implementation into national health systems is a global health priority if elimination of HIV as a public health threat is to be achieved by 2030. This systematic review aims to investigate VL monitoring outcomes in SSA, and to identify gaps and possible interventions to help nations meet their 2030 targets. A literature search of three electronic platforms (MEDLINE, EMBASE and Global Health) was undertaken from 1 January to 9 August 2024 to identify studies published in English and conducted in SSA. The primary outcome was the proportion of people living with HIV (PLHIV) on antiretroviral therapy (ART) with routine VL monitoring at the recommended time points (initially, 6 months, 12 months and annually). Secondary outcomes reported proportions of PLHIV who received routine VL monitoring who went on to complete the cascade of care after identified virological failure [enhanced adherence counselling (EAC), switch to second-line ART, and finally viral suppression]. The initial search identified 342 papers, of which 35 studies were included for narrative synthesis. Included studies reported on findings from 14 African countries and demonstrated extensive variation in rates of VL monitoring (range: 24.3-99.7%, mean: 63.8%). Results were more unfavourable in the latter steps of the viral load monitoring cascade, with a range of 0-88%, and a switch to second-line ART mean of 42% (range: 4.4-93%). Studies with additional support, and those with community-based models of care, had higher rates of VL testing and viral suppression. VL monitoring and management of virological failure are suboptimal in many SSA countries due to individual and health system-related challenges. Health system strengthening is vital to ensure the sustainability of HIV treatment programmes and the achievement of 95-95-95 targets by 2030.